Cochrane · systematic review · CD013228
Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes mellitus
Fullerton, B, Siebenhofer, A, Jeitler, K, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Short‐acting insulin analogues compared to regular human insulin for adults with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (N) Short‐acting insulin analogues vs regular human insulin | Peto OR 1.66 [0.41, 6.64] | 6 studies · 2519 participants | Moderate Downgraded: imprecision |
Macrovascular or microvascular complications Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |
Severe hypoglycaemic episodes (N) Short‐acting insulin analogues vs regular human insulin | no estimate extracted | 6 studies · 2509 participants | Low Downgraded: risk of bias |
Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month) Short‐acting insulin analogues vs regular human insulin | no estimate extracted | 7 studies · 2667 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
HbA1c (%) Short‐acting insulin analogues vs regular human insulin | no estimate extracted | 9 studies · 2608 participants | Low Downgraded: imprecision, inconsistency |
Health‐related quality of life (different scales used) Short‐acting insulin analogues vs regular human insulin | no estimate extracted | 2 studies · 2 participants | Very low Downgraded: risk of bias, imprecision |
Socioeconomic effects Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |